| Literature DB >> 31960599 |
Anna L Beale1,2,3, Carmela Cosentino3, Louise Segan2, Justin A Mariani1, Donna Vizi1, Shona Evans1, Shane Nanayakkara1,2,3, David M Kaye1,2,3.
Abstract
AIMS: Women are overrepresented amongst patients with heart failure with preserved ejection fraction (HFpEF); however, the underpinning mechanism for this asymmetric distribution is unclear. Pregnancy represents a potential gender-specific risk factor for HFpEF. It leads to significant physiological adaption, and increasing parity has been associated with some cardiovascular risk. We sought to examine the relationship between prior parity with the rest and exercise haemodynamic and echocardiographic profile of women with HFpEF. METHODS ANDEntities:
Keywords: Haemodynamics; Heart failure with preserved ejection fraction; Parity; Pregnancy; Sex characteristics
Mesh:
Year: 2020 PMID: 31960599 PMCID: PMC7083419 DOI: 10.1002/ehf2.12557
Source DB: PubMed Journal: ESC Heart Fail ISSN: 2055-5822
Baseline demographics in women according to parity category
| 0–2 births | ≥3 births |
| |
|---|---|---|---|
| Age (years) | 71 (67–73) | 75 (68–78) | 0.065 |
| BMI (kg/m2) | 30 (25–34) | 30 (26–34) | 0.68 |
| BNP at rest (ng/L) | 99 (50–170) | 104 (74–129) | 0.9 |
| NT‐proBNP at rest (ng/L) | 230 (171–533) | 672 (405–948) | 0.44 |
| NYHA class, %class III/IV | 50% | 61.5% | 0.49 |
| Total number of births | 48 | 97 | <0.001 |
| Co‐morbidities | |||
| Hypertension, | 21 (72%) | 22 (79%) | 0.82 |
| Atrial arrhythmia, | 14 (48%) | 13 (45%) | 1 |
| Diabetes mellitus, | 2 (7%) | 5 (17%) | 0.42 |
| IHD, | 4 (14%) | 5 (17%) | 1 |
| COPD, | 1 (3%) | 4 (14%) | 0.35 |
| Current/ex‐smoker, | 7 (39%) | 7 (30%) | 0.81 |
| Medications | |||
| ACE‐I/ARB (%) | 45% | 62% | 0.29 |
| Beta‐blocker (%) | 57% | 31% | 0.13 |
| MRA (%) | 22% | 31% | 0.7 |
| Calcium channel blocker (%) | 30% | 35% | 1 |
| Loop diuretic (%) | 13% | 31% | 0.25 |
| Thiazide diuretic (%) | 26% | 23% | 1 |
| Aspirin (%) | 44% | 39% | 0.94 |
| Second antiplatelet (%) | 9% | 0% | 0.42 |
| Oral anticoagulant (%) | 35% | 42% | 0.81 |
| Statin (%) | 52% | 54% | 1 |
| Level of education | |||
| High school | 53% | 55% | 0.69 |
| Tertiary | 29% | 35% | |
| Postgraduate | 18% | 10% | |
| Annual household income ($AU) | |||
| <50 000 | 45% | 47% | 0.73 |
| 50 000–100 000 | 45% | 42% | |
| >100 000 | 10% | 11% | |
| Frequency of work | |||
| Did not work | 15% | 35% | 0.17 |
| Part‐time | 81% | 65% | |
| Full‐time | 4% | 0% | |
ACE‐I, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BNP, B‐type natriuretic peptide; COPD, chronic obstructive pulmonary disease; IHD, ischaemic heart disease; MRA, mineralocorticoid receptor antagonist; NT‐proBNP, N‐terminal prohormone of brain natriuretic peptide; NYHA, New York Heart Association.
Invasive haemodynamics at rest and exercise according to parity category
| 0–2 births | ≥3 births |
| |
|---|---|---|---|
| Peak workload (W) | 46 (31–68) | 38 (24–51) | 0.04 |
| Rest HR (b.p.m.) | 67 ± 14 | 71 ± 15 | 0.29 |
| Exercise HR (b.p.m.) | 103 ± 24 | 100 ± 21 | 0.58 |
| Rest SBP (mmHg) | 147 ± 25 | 151 ± 23 | 0.48 |
| Exercise SBP (mmHg) | 177 ± 25 | 174 ± 28 | 0.64 |
| Rest RAP (mmHg) | 7 (5–9) | 6 (4–8) | 0.3 |
| Exercise RAP (mmHg) | 14 (12–17) | 16 (13–21) | 0.11 |
| Rest mean PAP (mmHg) | 20 (18–25) | 21 (18–27) | 0.65 |
| Exercise mean PAP (mmHg) | 43 (38–46) | 45 (41–49) | 0.14 |
| PCWP at rest (mmHg) | 13 (10–15) | 13 (10–14) | 0.53 |
| Exercise PCWP indexed to workload (mmHg/W) | 0.7 (0.4–1.1) | 0.9 (0.6–1.2) | 0.05 |
| ΔPCWP indexed to cardiac output (mmHg/L/min) | 4.6 (3.2–7.7) | 6.9 (4.5–11) | 0.03 |
| Rest CI (L/min/m2) | 2.8 ± 0.6 | 2.7 ± 0.6 | 0.44 |
| Exercise CI (L/min/m2) | 4.7 ± 1.2 | 4.3 ± 1.2 | 0.25 |
CI, cardiac index; HR, heart rate; PAP, pulmonary artery pressure; PCWP, pulmonary capillary wedge pressure; RAP, right atrial pressure; SBP, systolic blood pressure.
Figure 1Change in right atrial pressure, left, along with pulmonary capillary wedge pressure, right, with exercise according to parity category. PCWP, pulmonary capillary wedge pressure.
Figure 2Change in pulmonary capillary wedge pressure with exercise indexed to workload in men and women according to parity category. PCWP, pulmonary capillary wedge pressure.
Echocardiography at rest and exercise according to parity category
| 0–2 births | ≥3 births |
| |
|---|---|---|---|
| LVEF at rest (%) | 63 (60–66) | 60 (57–61) | 0.008 |
| LVEF at exercise (%) | 68 (66–70) | 65 (62–67) | 0.038 |
| LVMI (g/m2) | 84 (72–97) | 79 (67–92) | 0.31 |
| End‐diastolic septal wall thickness (mm) | 10 (10–11) | 10 (9–12) | 0.8 |
| End‐diastolic posterior wall thickness (mm) | 10 (9–10) | 9 (9–10) | 0.32 |
| LV end‐diastolic diameter | 46 (43–48) | 45 (43–50) | 0.92 |
| LV end‐systolic diameter | 29 (26–33) | 31 (27–35) | 0.31 |
| LAVI | 36 (30–44) | 43 (32–51) | 0.19 |
| LV global strain | −19 (−21 to −18) | −18 (−19 to −17) | 0.2 |
| RV global strain | −19 (−24 to −19) | −19 (−21 to −15) | 0.21 |
| LA global strain | 24 (20–26) | 22 (17–31) | 0.89 |
| RVSP at rest | 28 (23–42) | 34 (30–42) | 0.16 |
| TAPSE | 2.3 (2.1–2.8) | 2.2 (1.9–2.4) | 0.36 |
| E/e′ lateral at rest | 11.6 (10–13.3) | 10.3 (8.7–12.2) | 0.12 |
| E/e′ septal at rest | 14.4 (12.3–17) | 13.2 (11.2–19.2) | 0.68 |
| E/e′ mean at rest | 12.4 (11.6–15.6) | 11.3 (10.2–15.2) | 0.34 |
| E/e′ lateral at exercise | 12.9 (10.9–15.1) | 12 (10–13.4) | 0.47 |
| E/e′ septal at exercise | 14.4 (12.1–15.6) | 14.5 (11.9–17.2) | 0.93 |
| E/e′ mean at exercise | 13.7 (11.8–14.9) | 13.5 (10.9–14.8) | 0.68 |
LA, left atrial; LAVI, left atrial volume index; LV, left ventricular; LVEF, left ventricular ejection fraction; LVMI, left ventricular mass index; RV, right ventricular; RVSP, right ventricular systolic pressure; TAPSE, tricuspid annular plane systolic excursion.
Exercise variables reported for 35 women with exercise echocardiography.
Strain measurements were available for 24 (41%) of the cohort.
Figure 3Rest and exercise left ventricular ejection fraction (LVEF) according to parity category.
Vascular resistance, compliance, and elastance according to parity category
| Invasively derived values | |||
|---|---|---|---|
| 0–2 births | ≥3 births |
| |
| Rest SVR (mmHg/L/min) | 18.4 ± 6.9 | 20.3 ± 5.4 | 0.24 |
| Exercise SVR (mmHg/L/min) | 11.4 (9.4–15.8) | 11.5 (9.8–16.1) | 0.93 |
| Rest PVR (mmHg/L/min) | 1.6 (1.4–1.9) | 1.9 (1.6–2.4) | 0.046 |
| Exercise PVR (mmHg/L/min) | 1.4 (1–1.8) | 1.9 (2.4–2.4) | 0.024 |
| Systemic compliance at rest (mL/mmHg) | 1.1 (0.9–1.3) | 1 (0.8–1.2) | 0.21 |
| Systemic compliance at exercise (mL/mmHg) | 1 (0.9–1.3) | 1 (0.8–1.2) | 0.91 |
| ∆Systemic compliance (mL/mmHg) | 0.04 (−0.1 to 0.3) | 0 (−0.2 to 0.2) | 0.23 |
| Pulmonary compliance at rest (mL/mmHg) | 4.1 (3.2–5.2) | 3.2 (2.8–3.8) | 0.009 |
| Pulmonary compliance at exercise (mL/mmHg) | 2.5 (2.2–3.2) | 2.3 (1.8–2.8) | 0.15 |
| ∆Pulmonary compliance (mL/mmHg) | 1.5 (0.8–2.1) | 1.1 (0.3–1.5) | 0.16 |
| Ea at rest (mmHg/mL/m2) | 1.8 (1.4–2) | 2 (1.7–2.2) | 0.059 |
| Ea at exercise (mmHg/mL/m2) | 1.8 ± 0.4 | 1.9 ± 0.6 | 0.5 |
| ∆Ea (mmHg/mL) | −0.09 (−0.4 to 0.09) | 0.1 (−0.2 to 0.4) | 0.041 |
Ea, arterial elastance; PVR, pulmonary vascular resistance; SVR, systemic vascular resistance.
Ventricular elastance and ventricular–vascular coupling according to parity category
| 0–2 births | ≥3 births |
| |
|---|---|---|---|
| Ees at rest | 3.6 (2.8–4.5) | 3.4 (2.7–4.2) | 0.63 |
| Ees at exercise | 4.8 (4.1–7.3) | 4 (3.6–5) | 0.2 |
| ∆Ees | 1.7 (1.1–2.7) | 0.8 (0.4–1.3) | 0.046 |
| Ed at rest | 0.1 (0.09–0.2) | 0.1 (0.1–0.14) | 0.63 |
| Ed at exercise | 0.3 (0.3–0.4) | 0.3 (0.2–0.3) | 0.63 |
| ∆Ed | 0.2 (0.1–0.2) | 0.2 (0.1–0.2) | 0.89 |
| Ea/Ees at rest | 0.5 (0.4–0.6) | 0.6 (0.5–0.8) | 0.35 |
| Ea/Ees at exercise | 0.4 (0.3–0.4) | 0.5 (0.4–0.6) | 0.06 |
| ∆Ea/Ees | 0.1 (0.09–0.19) | 0.09 (0.06–0.2) | 0.88 |
Ea, arterial elastance; Ed, end‐diastolic elastance; Ees, end‐systolic elastance.
Figure 4Proposed mechanisms behind the association between multiparity and severity of exercise limitation in heart failure with preserved ejection fraction (HFpEF). LVEF, left ventricular ejection fraction; PCWP, pulmonary capillary wedge pressure; RA, right atrial.